Prostatype Genomics AB
Solna
About Prostatype Genomics AB
Prostatype Genomics AB manufactures, markets, and sells the prognostic gene test Prostatype. By giving a comprehensive assessment of the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under-treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $668.9K
- Funding stage: IPO
- Last round: Post-IPO Equity (Apr 2024)
- Ticker: sto:PROGEN
- Website: prostatypegenomics.com
- Phone: +46 (0)8-20 87 00
Industries & Categories
Biotechnology, Health Diagnostics, Manufacturing, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/prostatype-genomics-ab-2221050 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.